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Abstract Expression of wild type HFE reduces the ferritin
levels of cells in culture. In this report we demonstrate that the
predominant hereditary hemochromatosis mutation, C282Y2
HFE, does not reduce ferritin expression. However, the second
mutation, H63D HFE, reduces ferritin expression to a level
indistinguishable from cells expressing wild type HFE. Further,
two HFE cytoplasmic domain mutations engineered to disrupt
potential signal transduction, S335M and Y342C, were func-
tionally indistinguishable from wild type HFE in this assay, as
was soluble HFE. These results implicate a role for the
interaction of HFE with the transferrin receptor in lowering
cellular ferritin levels. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Hereditary hemochromatosis is a common, autosomal re-
cessive disease of iron metabolism [2]. Lack of functional
HFE in the cells of the duodenal crypts leads to chronic
absorption of iron [1,3^6]. The excess iron accumulates in
the cells of parenchymal tissues leading to oxidative damage
and multi-organ dysfunction [2]. The pathology of hereditary
hemochromatosis indicates that HFE plays a signi¢cant role
in regulated iron absorption and the maintenance of iron
homeostasis, but the exact mechanism by which HFE facili-
tates iron homeostasis is not yet understood.
The predominant mutation in HFE that leads to hereditary
hemochromatosis is a missense mutation which leads to the
conversion of a critical cysteine to tyrosine at amino acid 282
[1]. HFE is a non-classical major histocompatibility complex
class I type molecule that requires L-2-microglobulin binding
for proper folding and e⁄cient cell surface expression [4,7^
10]. The C282Y mutation prevents the formation of a disul-
¢de bond that stabilizes the L-2-microglobulin binding pocket
in HFE [9]. The inability of this mutant to fold correctly and
associate with L-2-microglobulin [8] results in reduced
amounts of HFE and ine⁄cient tra⁄cking to the cell surface
[7]. Lack of association with the transferrin receptor explains
why it does not localize to the endosome as does wild type
HFE [10^12].
A second HFE mutation has been identi¢ed in a signi¢cant
number of individuals with hereditary hemochromatosis. This
missense mutation converts amino acid 63 from histidine to
aspartic acid, disrupting the formation of a salt bridge with
the aspartic acid at position 95 [9]. The frequency of this
mutation is signi¢cantly increased in individuals with heredi-
tary hemochromatosis that are heterozygous for the C282Y
mutation. This mutation is often associated with an intermedi-
ate iron loading phenotype [1,13]. The interaction of H63D
HFE with transferrin receptor is not signi¢cantly di¡erent
from that of wild type HFE. It has approximately the same
a⁄nity for the transferrin receptor [14] and co-immunoprecip-
itates with the transferrin receptor [8]. Because the association
of HFE with the transferrin receptor is the main link between
HFE and iron homeostasis, how this mutation contributes to
iron overload is unclear.
Despite the e¡orts to understand the role of HFE in iron
homeostasis, the precise mechanism behind its function re-
mains unknown. Several groups have independently observed
an iron de¢cient phenotype in cell lines transfected with HFE
that is evidenced by increased transferrin receptor expression,
decreased ferritin expression and an increase in IRP ac-
tivity [11,15,16]. The labile iron pool is hypothesized to be
reduced because HFE reduces iron uptake from transferrin
[15^19].
In this report we have examined HFE disease alleles for an
iron de¢cient phenotype in cultured cell lines based on their
ability to reduce ferritin levels when HFE is expressed. Ferri-
tin levels were assayed to investigate the possibility that HFE
uses its cytoplasmic domain to initiate a signal transduction
cascade that might induce the low iron phenotype. Finally,
ferritin levels in cells treated with a soluble form of HFE
were measured to determine whether the transmembrane or
cytoplasmic domain of HFE might modify some other cyto-
plasmic component of iron metabolism that would produce
the low iron phenotype. We conclude that HFE does not
require the transmembrane or cytoplasmic domain to lower
ferritin levels in HEK 293 cells, but most likely does require
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cell surface expression and association with the transferrin
receptor to induce the low iron phenotype.
2. Materials and methods
2.1. Site-directed mutagenesis of HFE
The isolation of the H63D cDNA and generation of the C282Y
mutation have been previously described [7]. A standard polymerase
chain reaction (PCR) mutagenesis approach was utilized to generate
the S335M and Y342C mutations. Two overlapping fragments with
the appropriate base changes were produced in a ¢rst round PCR
reaction. The product of the ¢rst reaction was then combined with
the primers previously described [7] to yield the HFE mutant with the
FLAG epitope.
2.2. Cell lines
The fWTHFE/tTA HeLa cell line expressing FLAG epitope-tagged
HFE (fHFE) under the tetracycline responsive promoter has been
previously described [11]. Cells were grown in Dulbecco’s modi¢ed
Eagle’s essential medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 400 Wg/ml G418 (Geneticin, Calbiochem), 200
ng/ml puromycin, and with (HFE3) or without (HFE+) 2 Wg/ml
tetracycline. The HEK 293 cell lines were co-transfected with the
plasmids for the individual HFE mutations described above, and a
plasmid containing the coding sequence for human L-2-microglobulin
[7]. Isolated HFE-expressing clones were grown in DMEM supple-
mented with 10% FBS and 600 Wg/ml G418.
2.3. Cell treatments
Cells were plated into 35 mm dishes in DMEM with 10% FBS and
50 nM human transferrin. After 3 days in culture, the growth medium
was changed and desferoxamine was added to a ¢nal concentration of
50 WM, Fe(NTA)4 was added to a ¢nal concentration of 100 WM, or
soluble HFE (a kind gift of Pamela Bjorkman, California Institute of
Technology, CA, USA) was added to a ¢nal concentration of 0.5 or
1 WM. Cells were grown for at least 16 h in the treated medium before
they were lyzed.
2.4. Immunodetection of HFE and ferritin
Cells were lyzed with NET-Triton bu¡er (150 mM NaCl, 5 mM
EDTA, 10 mM Tris, 1% Triton X-100, pH 7.4). Samples (V300 Wg)
were diluted with Laemmli bu¡er [20] and subjected to electrophoresis
on denaturing 12% SDS^polyacrylamide gels under reducing condi-
tions. The proteins were transferred to nitrocellulose. Immunoblot
analysis of HFE was performed as described previously using rabbit
anti-HFE antibody EX1 (1:500 dilution) [7] and sheep anti-rabbit
antibody conjugated to horseradish peroxidase (1:10 000 dilution,
Roche Molecular Biochemicals). Immunoblot analysis of ferritin
was performed as described previously [11] using rabbit anti-human
ferritin antibody (1:1000 dilution, Dako), and sheep anti-rabbit anti-
body conjugated to horseradish peroxidase (1:10 000 dilution, Roche
Molecular Biochemicals). Western blots were developed using chem-
iluminescence (Super Signal, Pierce) per the manufacturer’s directions.
3. Results
Wild type and mutant forms of HFE were stably expressed
in HEK 293 cells. Immunoblot analysis identi¢ed stable ex-
pression of the V40^45 kDa HFE product in all cell types
except that of the parental HEK 293 cell line in which no
detectable HFE was identi¢ed (Fig. 1).
Expression of HFE induces an iron de¢cient phenotype as
indicated by reduced ferritin levels in HeLa cells [11,15^17].
To con¢rm that HFE had the same e¡ect in HEK 293 cells,
analysis of ferritin levels was performed for parental HEK 293
cells and those expressing wild type HFE (Fig. 2). Immuno-
blot analysis revealed that HFE expression reduced ferritin
levels under standard tissue culture conditions. HFE did not
prevent the cells from responding to changes in iron status, as
ferritin expression decreased in the presence of the iron che-
lator, desferoxamine, and increased with the addition of Fe-
NTA. Identical results were obtained in HEK 293 cells trans-
fected without a FLAG epitope-tagged wild type HFE, indi-
cating the FLAG epitope is not responsible for the low iron
phenotype (data not shown). These results recapitulate the
phenotype that was observed previously in fWTHFE/tTA
HeLa cells [11,17].
While the reduction in cellular ferritin levels in cells express-
ing HFE has been independently observed by several investi-
gators [11,15^17], its correlation with iron homeostasis for the
entire organism is not fully understood. To determine whether
this low iron phenotype is re£ected in the disease state, we
compared the iron de¢cient phenotype for HEK 293 cells
expressing wild type HFE with those expressing the two he-
reditary hemochromatosis disease alleles (Fig. 3). Immunoblot
analysis revealed that under standard tissue culture condi-
tions, C282Y HFE did not reduce ferritin levels to that of
wild type HFE-expressing cells. The ferritin levels detected
in C282Y HFE/HEK 293 cells were not signi¢cantly di¡erent
from that of the HEK 293 parental cell line (data not shown).
Conversely the H63D HFE disease allele, whose contribution
to the disease state may not be as severe as the C282Y HFE,
Fig. 1. Characterization of stable HFE expression in WT-, C282Y-,
H63D-, S335M-, Y342C HFE/HEK 293 cell lines. Parental HEK
293 cells (lane 3), like fWTHFE/tTA HeLa cells with tetracycline
added to turn o¡ HFE (lane 1), did not express detectable levels of
HFE as assayed by immunoblot. Wild type (lane 4) and mutant
HFEs (lanes 5^8) were stably expressed in HEK 293 cells. The mo-
lecular weight of HFE in these cells was slightly less than that of
HFE in fWTHFE/tTA HeLa cells (lane 2), probably due to di¡eren-
ces in the extent of glycosylation in the two cell lines [11]. These re-
sults are representative of more than three independent experiments
with similar results.
Fig. 2. Wild type HFE-expression reduced ferritin levels in HEK
293 cells. Immunoblot revealed that full length HFE expression re-
duced ferritin levels in HEK 293 cells grown under standard tissue
culture conditions (C, lane 6) when compared to the parental cell
line (C, lane 3) as it does in fWTHFE/tTA HeLa cells (lane 1 versus
lane 2). Ferritin levels still responded to cellular iron status in the
presence of HFE, however, since they decreased with the addition
of desferoxamine, an iron chelator (Df, lane 7), and increased with
the addition of Fe(NTA)4, an iron salt (Fe, lane 8). These results
are representative of more than three independent experiments with
similar results.
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did recapitulate the wild type HFE phenotype. Ferritin levels
in the H63D HFE cells were reduced to a level similar to
those of HEK 293 cells expressing wild type HFE.
Despite extensive characterization of the interaction be-
tween HFE and the transferrin receptor, the exact mechanism
by which HFE lowers ferritin levels has not been determined.
One possible mechanism by which HFE could function would
be through a signal transduction pathway initiated by the
cytoplasmic domain of HFE. We assayed for the iron de¢cient
phenotype in cell lines with either the Y342 or S335 in the
cytoplasmic domain changed to C or M, respectively (Fig. 4).
The original tyrosine and serine amino acids are potential
candidates for phosphorylation. Immunoblot analysis indi-
cated that cells expressing Y342C and S335M HFE showed
reduced ferritin levels compared to those of the HEK 293
parent cells. The ferritin content of these cell lines was not
signi¢cantly di¡erent from those of the HEK 293 cells ex-
pressing wild type HFE (data not shown), indicating these
mutants were functional according to the limits of this assay.
To determine the involvement of other elements in the HFE
cytoplasmic domain, the ability of soluble HFE to induce the
same low iron phenotype as the full length HFE in HEK 293
cells was assayed. A soluble form of HFE lacking the cyto-
plasmic and transmembrane domains has been used to inves-
tigate the interaction of HFE and the transferrin receptor [9].
This form of HFE has high a⁄nity for the transferrin receptor
[8,9], and reduces the a⁄nity of the transferrin receptor for
transferrin [8,18]. Incubation of cells with soluble HFE re-
sulted in a reduction of ferritin levels in parental HEK 293
cells in a concentration-dependent manner (Fig. 5). Super¢-
cially, the soluble HFE appears to reduce ferritin levels to a
greater extent than the full length HFE (Fig. 5). We repeated
the experiments three times and when the starting amounts of
ferritin in both cell lines were the same, then no reproducible
di¡erence was detected between the ¢nal levels of ferritin in
cells containing full length or in those treated with soluble
HFE (data not shown). Like the results from the Y342C
and the S335M mutants, the result that the soluble HFE low-
ers ferritin levels also argues against the possibility that the
transmembrane or cytoplasmic domains of HFE modulate
cytoplasmic components of iron metabolism.
4. Discussion
A comparison of the wild type and disease-associated forms
of HFE on ferritin levels in cultured cells was assessed. We
observed that wild type HFE expressed in HEK 293 cells
produces the same low iron phenotype that was originally
identi¢ed in HFE-expressing HeLa cells [11,15^17].
C282Y HFE is severely reduced in function because it does
not fold correctly [9] as manifested by; lack of association
with L-2-microglobulin [7], lack of e⁄cient tra⁄cking to the
cell surface [7,10], lack of association with the transferrin re-
ceptor [8] and the inability to maintain normal iron homeo-
stasis in mice [6]. In this study, we show that it is also unable
to recapitulate the low iron phenotype induced by wild type
HFE in HEK 293 cells. The observation that this mutation in
HFE does not reduce ferritin expression suggests that HFE
must be e⁄ciently expressed at the cell surface and/or tightly
associated with the transferrin receptor in order to produce
the low iron phenotype.
Unlike C282Y HFE, H63D HFE has been shown to tra⁄c
to the cell surface [7,10] and to associate with transferrin
Fig. 5. Soluble HFE reduces ferritin expression in HEK 293 cells.
Immunoblot reveals that addition of soluble HFE (sHFE) to the
growth medium of parental HEK 293 cells reduced ferritin expres-
sion (lower panel, lane 3 versus lanes 4 and 5) as full length HFE
does in fWTHFE/tTA HeLa cells (lower panel, lane 1 versus lane
2). Immunoblot analysis of soluble HFE con¢rmed the association
of soluble HFE with these cells (upper panel, lanes 4 and 5). These
results are representative of more than three independent experi-
ments with similar results.
Fig. 4. Y342C and S335M HFE expression reduced ferritin levels to
that of wild type HFE in HEK 293 cells. Expression of the Y342C
(lanes 4^6) and S335M (lanes 7^9) HFEs in HEK 293 cells reduced
ferritin expression to levels below that of the parental cell line (lanes
1^3) as assayed by immunoblot. Ferritin levels responded to cellular
iron status. All cell types expressed less ferritin in the presence of
desferoxamine (Df, lanes 2, 5, and 8). Additionally, all cell types in-
creased ferritin expression in the presence of Fe(NTA)4 (Fe, lanes 3,
6 and 9). These results are representative of more than three inde-
pendent experiments with similar results.
Fig. 3. C282Y HFE-expression did not reduce ferritin levels while
H63D HFE-expression reduced ferritin levels to that of wild type
HFE in HEK 293 cells. Expression of the C282Y HFE disease allele
protein product in HEK 293 cells grown under standard tissue cul-
ture conditions (C, lane 4) did not reduce ferritin levels like that of
wild type HFE (C, lane 1) as assayed by immunoblot. However, fer-
ritin levels did respond to cellular iron status as they decreased with
the addition of desferoxamine (Df, lane 5) and increased with the
addition of Fe(NTA)4 (Fe, lane 6). Expression of the H63D HFE
disease allele protein product in HEK 293 cells grown under stan-
dard tissue culture conditions (C, lane 7) reduced ferritin expression
to the same level found in wild type HFE-expressing cells (C, lane
1). Like wild type HFE, ferritin levels responded to cellular iron sta-
tus, decreasing in the presence of desferoxamine (Df, lanes 2 and 8)
and increasing in the presence of Fe(NTA)4 (Fe, lanes 3 and 9).
These results are representative of more than three independent ex-
periments with similar results.
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receptor [8]. In this study, we show that cells transfected with
the H63D HFE also have a low iron phenotype. These ob-
servations suggest that the H63D HFE would be functional in
vivo and yet, the H63D allele occurs with increased frequency
in individuals diagnosed with hereditary hemochromatosis
[1,13]. The di¡erence between the disease phenotype observed
in humans with the H63D mutation and the wild type phe-
notype observed in the H63D HFE-expressing cell culture
system may be the level of expression of the protein. Since
the H63D HFE lacks the ability to form a salt bridge that
may be important to the stability of the protein [9], the H63D
HFE may be less stable than the wild type HFE. A small but
signi¢cant decrease in functional HFE in vivo may lead to
iron overload over the course of a lifetime. The hereditary
hemochromatosis pathology resulting from the H63D muta-
tion is milder than that of individuals homozygous for the
C282Y HFE mutation.
The importance of the association between the extracellular
domains of HFE and transferrin receptor is underscored by
the observation that mutations to the cytoplasmic domain of
HFE do not a¡ect the low iron phenotype. We observed that
Y342C and S335M HFEs reduced ferritin levels. These results
indicate that the low iron phenotype is not the result of signal
transduction through the tyrosine or serine amino acid resi-
dues in the cytoplasmic domain of HFE. Furthermore, the
decrease in ferritin levels observed in cells treated with soluble
HFE supports the hypothesis that the phenotype is mediated
solely through interaction of the extracellular domains of
HFE and the transferrin receptor. However, these results do
not rule out the possibility that HFE binding to the trans-
ferrin receptor ectodomain propagates conformational
changes in the transferrin receptor cytoplasmic domain that
might modulate signal transduction cascades or cytoplasmic
components of cellular iron metabolism.
Our results support the hypothesis that HFE acts through
the transferrin receptor-mediated pathway of iron uptake to
regulate cellular iron homeostasis. Severe mutations in HFE,
such as the C282Y mutation, which prevents association with
the transferrin receptor, do not manifest a low iron pheno-
type. These results predict that mutations in HFE that lower
the a⁄nity of HFE for the transferrin receptor, such as the
W103A HFE [14], would not result in the low iron phenotype.
Recent results indicate that this is indeed true [12]. Future
experiments will be directed at determining the mechanism
by which the HFE interaction with transferrin receptor in
the extracellular domains reduces iron uptake from transfer-
rin.
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